67,691 Shares in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Purchased by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC acquired a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 67,691 shares of the biotechnology company’s stock, valued at approximately $279,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Ironwood Pharmaceuticals by 21.8% in the 1st quarter. Vanguard Group Inc. now owns 19,521,366 shares of the biotechnology company’s stock worth $170,031,000 after buying an additional 3,487,821 shares in the last quarter. Pacer Advisors Inc. raised its stake in Ironwood Pharmaceuticals by 23.6% in the 2nd quarter. Pacer Advisors Inc. now owns 8,907,639 shares of the biotechnology company’s stock valued at $58,078,000 after purchasing an additional 1,701,452 shares during the last quarter. Renaissance Technologies LLC raised its stake in Ironwood Pharmaceuticals by 20.7% in the 2nd quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company’s stock valued at $55,889,000 after purchasing an additional 1,472,097 shares during the last quarter. Armistice Capital LLC raised its stake in Ironwood Pharmaceuticals by 44.4% in the 2nd quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company’s stock valued at $50,856,000 after purchasing an additional 2,400,000 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its stake in Ironwood Pharmaceuticals by 40.8% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 4,235,580 shares of the biotechnology company’s stock valued at $36,892,000 after purchasing an additional 1,226,377 shares during the last quarter.

Analyst Ratings Changes

Several brokerages recently weighed in on IRWD. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Leerink Partners began coverage on shares of Ironwood Pharmaceuticals in a research note on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price for the company. Craig Hallum cut their target price on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Wells Fargo & Company cut their target price on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, August 9th. Finally, Capital One Financial downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $12.00 to $4.00 in a research note on Thursday, August 8th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Ironwood Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $12.17.

Insider Buying and Selling

In related news, insider Minardo John sold 9,910 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $4.27, for a total transaction of $42,315.70. Following the completion of the sale, the insider now owns 284,661 shares of the company’s stock, valued at approximately $1,215,502.47. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Price Performance

NASDAQ IRWD opened at $4.40 on Monday. Ironwood Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $15.70. The company has a 50-day moving average of $4.46 and a 200-day moving average of $5.97. The company has a market cap of $688.73 million, a P/E ratio of -0.65 and a beta of 0.48.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.